A commercialized dietary supplement alleviates joint pain in community adults: A double-blind, placebo-controlled community trial

来自 EBSCO

阅读量：

作者：

展开

摘要：

The purpose of this study was to assess the effect of 8-weeks ingestion of a commercialized joint pain dietary supplement (InstaflexTM Joint Support, Direct Digital, Charlotte, NC) compared to placebo on joint pain, stiffness, and function in adults with self-reported joint pain. InstaflexTM is a joint pain supplement containing glucosamine sulfate, methylsufonlylmethane (MSM), white willow bark extract (15% salicin), ginger root concentrate, boswella serrata extract (65% boswellic acid), turmeric root extract, cayenne, and hyaluronic acid. Subjects included 100 men and women, ages 50-75 years, with a history (>3 months) of joint pain, and were randomized to InstaflexTM or placebo (3 colored gel capsules per day for 8 weeks, double-blind administration). Subjects agreed to avoid the use of non-steroidal anti-inflammatory drugs (NSAID) and all other medications and supplements targeted for joint pain. Primary outcome measures were obtained pre- and post-study and included joint pain severity, stiffness, and function (Western Ontario and McMaster Universities [WOMAC]), and secondary outcome measures included health-related quality of life (Short Form 36 or SF-36), systemic inflammation (serum C-reactive protein and 9 plasma cytokines), and physical function (6-minute walk test). Joint pain symptom severity was assessed bi-weekly using a 12-point Likert visual scale (12-VS). Joint pain severity was significantly reduced in InstaflexTM compared to placebo (8-week WOMAC, [downwards arrow]37% versus [downwards arrow]16%, respectively, interaction effect P = 0.025), with group differences using the 12-VS emerging by week 4 of the study (interaction effect, P = 0.0125). Improvements in ability to perform daily activities and stiffness scores in InstaflexTM compared to placebo were most evident for the 74% of subjects reporting knee pain (8-week WOMAC function score, [downwards arrow]39% versus [downwards arrow]14%, respectively, interaction effect P = 0.027; stiffness score, [downwards arrow]30% versus [downwards arrow]12%, respectively, interaction effect P = 0.081). Patterns of change in SF-36, systemic inflammation biomarkers, and the 6-minute walk test did not differ significantly between groups during the 8-week study CONCLUSIONS: Results from this randomized, double blind, placebo-controlled community trial support the use of the InstaflexTM dietary supplement in alleviating joint pain severity in middle-aged and older adults, with mitigation of difficulty performing daily activities most apparent in subjects with knee pain.Trial registration: ClinicalTrials.gov Identifier: NCT01956500.

展开

关键词：

Quality of life Glucosamine Physical function Inflammation Food Science and Technology

DOI：

10.1186/1475-2891-12-154

被引量：

年份：

2013